Literature DB >> 19298559

Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations.

Serge Sicouri1, Luiz Belardinelli, Leif Carlsson, Charles Antzelevitch.   

Abstract

OBJECTIVES: To examine the effects of chronic amiodarone on the electrophysiology of canine pulmonary vein (PV) sleeve preparations and left ventricular wedge preparation.
BACKGROUND: Amiodarone is commonly used for the treatment of ventricular and supraventricular arrhythmias. Ectopic activity arising from the PV plays a prominent role in the development of atrial fibrillation (AF).
METHODS: Standard microelectrode techniques were used to evaluate the electrophysiological characteristics of superfused PV sleeve (left superior or inferior) and arterially perfused left ventricular (LV) wedge preparations isolated from untreated and chronic amiodarone-treated dogs (amiodarone, 40 mg/kg daily for 6 weeks).
RESULTS: In PV sleeves, chronic amiodarone (n = 6) induced a significant increase in action potential duration at 90% repolarization (APD90) and a significant use-dependent reduction in Vmax leading to 1:1 activation failure at long cycle lengths (basic cycle length of 124 +/- 15 ms in control vs 420 +/- 320 ms after chronic amiodarone [P < 0.01]). Diastolic threshold of excitation increased from 0.3 +/- 0.2 to 1.8 +/- 0.7 mA (P < 0.01). Delayed and late phase 3 early afterdepolarizations and triggered activity could be induced in PV sleeve preparations using acetylcholine (ACh, 1 microM), high calcium ([Ca2+]o = 5.4 mM), isoproterenol (Iso, 1 microM), or their combination in 6 of 6 untreated PV sleeves, but in only 1 of 5 chronic amiodarone-treated PV sleeve preparations. Vmax, conduction velocity, and 1:1 activation failure were much more affected in PV sleeves versus LV wedge preparations isolated from amiodarone-treated animals.
CONCLUSIONS: The results point to potent effects of chronic amiodarone to preferentially suppress arrhythmogenic substrates and triggers arising from the PV sleeves of the dog.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19298559      PMCID: PMC2730672          DOI: 10.1111/j.1540-8167.2009.01449.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  44 in total

1.  Amiodarone pharmacokinetics.

Authors:  D W Holt; G T Tucker; P R Jackson; W J McKenna
Journal:  Br J Clin Pract Suppl       Date:  1986-04

2.  Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts.

Authors:  E A Sosunov; E P Anyukhovsky; M R Rosen
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

3.  A comparison of the electrophysiologic effects of acute and chronic amiodarone administration on canine Purkinje fibers.

Authors:  J D Gallagher; J Bianchi; L J Gessman
Journal:  J Cardiovasc Pharmacol       Date:  1989-05       Impact factor: 3.105

4.  Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart.

Authors:  S Sicouri; S Moro; S Litovsky; M V Elizari; C Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  1997-11

5.  Pharmacokinetics and regional electrophysiological effects of intracoronary amiodarone administration.

Authors:  J N Nanas; J W Mason
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

6.  Inhibitory effect of amiodarone on the muscarinic acetylcholine receptor-operated potassium current in guinea pig atrial cells.

Authors:  Y Watanabe; Y Hara; M Tamagawa; H Nakaya
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

7.  Relation between repolarization and refractoriness in the human ventricle: cycle length dependence and effect of procainamide.

Authors:  R J Lee; L B Liem; T J Cohen; M R Franz
Journal:  J Am Coll Cardiol       Date:  1992-03-01       Impact factor: 24.094

8.  Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction.

Authors:  F Morady; L A DiCarlo; R B Krol; J M Baerman; M de Buitleir
Journal:  J Am Coll Cardiol       Date:  1986-01       Impact factor: 24.094

9.  Mechanisms of depressed conduction from long-term amiodarone therapy in canine myocardium.

Authors:  J H Levine; E N Moore; A H Kadish; H F Weisman; C W Balke; R F Hanich; J F Spear
Journal:  Circulation       Date:  1988-09       Impact factor: 29.690

10.  Acute effects of amiodarone on membrane properties, refractoriness, and conduction in guinea pig papillary muscles.

Authors:  T Maruyama; L C Richardson; W Sun; J J McCarthy; L S Gettes
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

View more
  16 in total

1.  Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine.

Authors:  Serge Sicouri; Jonathan Blazek; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-03-09

Review 2.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

3.  Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2011-10-17       Impact factor: 4.030

4.  Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Marc Pourrier; John K Gibson; Joseph J Lynch; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2011-10-20       Impact factor: 6.343

5.  Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.

Authors:  Alexander Burashnikov; Alyssa Petroski; Dan Hu; Hector Barajas-Martinez; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2011-08-30       Impact factor: 6.343

6.  Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves.

Authors:  Serge Sicouri; Leif Carlsson; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2010-04-01       Impact factor: 4.030

7.  The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.

Authors:  Gerrit Frommeyer; André Mittelstedt; Julian Wolfes; Christian Ellermann; Simon Kochhäuser; Patrick Leitz; Dirk G Dechering; Lars Eckardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-08-06       Impact factor: 3.000

8.  Electrophysiological mechanisms of sophocarpine as a potential antiarrhythmic agent.

Authors:  Zhi-fang Yang; Ci-zhen Li; Wei Wang; Ying-min Chen; Ying Zhang; Yuan-mou Liu; Hong-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-01-24       Impact factor: 6.150

9.  Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.

Authors:  Serge Sicouri; Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-01

10.  Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation.

Authors:  Serge Sicouri; Charles Antzelevitch
Journal:  Electrofisiol Arritm       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.